Reports
Sale
Bullous Pemphigoid Market Size, Share, Trends, Analysis: By Treatment Type: Tablets, Capsules, Injectable, Other; By Diagnosis: Skin Biopsy, Physical Examination, Blood Test; By Drug Type: Immunosuppressant Medication, Steroids, Antibiotics & Antiseptics; By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Bullous Pemphigoid Market Outlook
The bullous pemphigoid market size in the seven major markets is expected to grow at a CAGR of 17.7% during the forecast period of 2024-2032, likely to be driven by the rising incidence of geriatric population and increasing research activities to develop effective treatment solutions for patients across the major markets.
Bullous Pemphigoid Market Overview
Bullous pemphigoid is an autoimmune subepidermal blistering disease that causes large fluid-filled blisters on the skin. Common symptoms include large blisters that do not rupture easily when touched, itching skin, eczema, or a hive-like rashes. Mucous membrane involvement may occur in 10-40% of the patients. In the United States, annual incidence is 6 to 13 new cases per million people while Central Europe witnesses 12 to 13 new cases per million. The incidence is similar in males and females; however, pregnant women are prone to get affected by a bullous pemphigoid variant, known as pemphigoid gestationis (PG). It develops in the later stages of the pregnancy (mostly second or third trimester) and has an estimated incidence of 1 case in 50,000 to 60,000 pregnancies.
The bullous pemphigoid market demand is directly impacted by the growing geriatric population as the condition is prevalent in the older generation, especially individuals aged 60 years or above. While the actual cause is unknown, bullous pemphigoid may be triggered by some medications, ultraviolet light therapy, and radiation as well.
Rising Number of Drugs under Investigation for Effective Treatment
In September 2023, the results of a study conducted at the National Autoimmune Bullous Diseases Cooperative Group of China revealed that Dupilumab treatment helped in easing bullous pemphigoid symptoms. Inflammation of TH2 is a well-known factor for disease pathogenesis and Dupilumab works by blocking IL-4Rα to downregulate a TH2-related signal pathway. With the help of this mechanism, the drug has aided disease control by 87% within 4 weeks of treatment initiation. The increasing number of drugs under clinical investigation are a key indicator of bullous pemphigoid market growth.
Rising Adoption of Combination Therapies
With increasing advancements in drug and antibody development, and better understanding of the disease on a genetic level, novel drugs are being investigated to address a wider range of symptoms and offer personalized treatment to patients. Consequently, the application of combination therapies is one of the major bullous pemphigoid market trends. In November 2023, research conducted at the Department of Dermatology at the University of California revealed that Rituximab (RTX) and omalizumab (OMZ) combination treatment demonstrated promising results on patients by reducing severe symptoms.
Increased Research on Disease Pathogenesis to Meet the Rising Bullous Pemphigoid Market Demand
Over 50% of the untreated bullous pemphigoid patients exhibit rising levels of blood eosinophils, making eosinophil infiltration a common characteristic of skin lesions. As a result, there has been significant emphasis on bringing effective solutions that treat the complications associated with the condition. In such cases, Bertilimumab , a humanized monoclonal antibody targeting eotaxin-1, is the latest drug being investigated for treating the condition. Simultaneously, Nemolizumab is also being considered as a potential medication to treat bullous pemphigoid in the future.
Surge in Research Activities to Offer Treatment for Prolonged and Treatment Resistant Symptoms
Bullous pemphigoid treatment is tailored on the basis of the severity of the condition and the patient’s history. The advancements in diagnostic technologies with improved histological evaluations also bolster the bullous pemphigoid market share. Oral steroids and systemic corticosteroids are the standard therapeutic options used. For patients with prolonged and resistant disease, long-term steroid treatment with a steroid-sparing immunomodulatory agent, such as tetracycline, intravenous immunoglobulin (IVIG), nicotinamide or dapsone, or immunosuppressive medications is administered.
Bullous Pemphigoid Market Segmentation
Market Breakup by Treatment Type
- Tablets
- Capsules
- Injectable
- Other
Market Breakup by Diagnosis
- Skin Biopsy
- Physical Examination
- Blood Test
Market by Drug Type
- Immunosuppressant Medication
- Steroids
- Antibiotics and Antiseptics
- Pain Relief Medication
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Bullous Pemphigoid Market Regional Analysis
In the forecast period, the United States is expected to lead the bullous pemphigoid market share, which can be attributed to higher incidence of neurological disorders such as stroke and dementia. The existence of key healthcare companies and a well-informed healthcare professional staff also adds significant value to the market. Several pharmaceutical companies are currently expanding their product portfolios to offer improved solutions to patients.
With a higher prevalence of geriatric population, Europe is another major market for bullous pemphigoid. With a robust healthcare infrastructure, the region is home to some influential academics and research institutions which contribute to the latest enhancements in treatment development. In addition, partnerships between firms and universities are also leading to increased market size.
Japan is one of the leading markets in the Asia Pacific region, based on value. However, emerging economies such as India, China, and South Korea are also projected to witness a substantial boost in the bullous pemphigoid market value in upcoming years. The increasing emphasis on offering improved healthcare services and development in medical infrastructure is one of the key reasons for growth. Owing to the easy availability of resources and noteworthy academic potential, various companies are investing in building research facilities to develop effective therapies for patients.
Bullous Pemphigoid Market: Competitor Landscape
In July 2022, Almirall, S.A. (ALM) launched an open innovation platform to establish collaborations in dermatological research. The initiative was based on inviting advanced therapies, small molecules, and biologics for rare dermatological indications such as pemphigus vulgaris and bullous pemphigoid, among others. The market is witnessing a similar trend of growth as major companies are stepping up to offer funds and partnerships to innovative solutions.
The key features of the bullous pemphigoid market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Almirall
- Pfizer Inc.
- Greenstone LLC
- F. Hoffmann-La Roche Ltd
- SiriusLabs
- Teva Pharmaceutical Industries Ltd
- Astellas Pharma Inc.
- Aegis Lifesciences Pvt. Ltd
- Novartis AG
- Mylan N.V.
- Baxter
- Bayer AG
- Omega Laboratories
- Merck KGaA.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Bullous Pemphigoid Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Bullous Pemphigoid Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.1 Germany Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.2 France Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.3 Italy Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.4 Spain Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Bullous Pemphigoid Epidemiology Forecast (2017-2032)
5.4 Japan Bullous Pemphigoid Epidemiology Forecast (2017-2032)
6 Bullous Pemphigoid Market Overview – Seven Major Markets
6.1 Bullous Pemphigoid Market Historical Value (2017-2023)
6.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
7 Bullous Pemphigoid Market Landscape – Seven Major Markets
7.1 Bullous Pemphigoid: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Bullous Pemphigoid Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Bullous Pemphigoid Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Bullous Pemphigoid Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Bullous Pemphigoid Market Segmentation – Seven Major Markets
11.1 Bullous Pemphigoid Market by Treatment Type
11.1.1 Market Overview
11.1.2 Tablets
11.1.3 Capsules
11.1.4 Injectable
11.1.5 Other
11.2 Bullous Pemphigoid Market by Diagnosis
11.2.1 Market Overview
11.2.2 Skin Biopsy
11.2.3 Physical Examination
11.2.4 Blood Test
11.3 Bullous Pemphigoid Market by Drug Type
11.3.1 Market Overview
11.3.2 Immunosuppressant Medication
11.3.3 Steroids
11.3.4 Antibiotics & Antiseptics
11.3.5 Pain Relief Medication
11.4 Bullous Pemphigoid Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Bullous Pemphigoid Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Others
11.6 Bullous Pemphigoid Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Bullous Pemphigoid Market
12.1 Bullous Pemphigoid Market Historical Value (2017-2023)
12.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
12.3 Bullous Pemphigoid Market by Diagnosis Type
12.4 Bullous Pemphigoid Market by Treatment Type
13 EU-4 and United Kingdom Bullous Pemphigoid Market
13.1 Bullous Pemphigoid Market Historical Value (2017-2023)
13.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
13.3 Germany Bullous Pemphigoid Market Overview
13.3.1 Bullous Pemphigoid Market by Diagnosis Type
13.3.2 Bullous Pemphigoid Market by Treatment Type
13.4 France Bullous Pemphigoid Market Overview
13.4.1 Bullous Pemphigoid Market by Diagnosis Type
13.4.2 Bullous Pemphigoid Market by Treatment Type
13.5 Italy Bullous Pemphigoid Market Overview
13.5.1 Bullous Pemphigoid Market by Diagnosis Type
13.5.2 Bullous Pemphigoid Market by Treatment Type
13.6 Spain Bullous Pemphigoid Market Overview
13.6.1 Bullous Pemphigoid Market by Diagnosis Type
13.6.2 Bullous Pemphigoid Market by Treatment Type
13.7 United Kingdom Bullous Pemphigoid Market Overview
13.7.1 Bullous Pemphigoid Market by Diagnosis Type
13.7.2 Bullous Pemphigoid Market by Treatment Type
14 Japan Bullous Pemphigoid Market
14.1 Bullous Pemphigoid Market Historical Value (2017-2023)
14.2 Bullous Pemphigoid Market Forecast Value (2024-2032)
14.3 Bullous Pemphigoid Market by Diagnosis Type
14.4 Bullous Pemphigoid Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Almirall
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Pfizer Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Greenstone LLC
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 F. Hoffmann-La Roche Ltd
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 SiriusLabs
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Teva Pharmaceutical Industries Ltd
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Astellas Pharma Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Aegis Lifesciences Pvt. Ltd
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Novartis AG
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Mylan N.V.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Baxter
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Bayer AG
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Omega Laboratories
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Merck KGaA.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Bullous Pemphigoid Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 17.7% during the forecast period of 2024-2032, driven by the increasing incidence of geriatric population.
The market demand is driven by the increasing incidence of bullous pemphigoid cases, along with rising influx of funds to increase research activities in the healthcare industry and drug development activities.
The current market trend involves the application of combination therapies to offer improved and precise treatment options to patients. Rituximab (RTX) and omalizumab (OMZ) have been administered to patients and have shown promising results by reducing the severity of the condition.
Based on treatment types, the market is divided into tablets, capsules, and injectable, among other.
The route of administration can be oral and parenteral, among others.
Major end users include hospitals and speciality clinics, among others.
The drugs available in the market include immunosuppressant medication, steroids, pain relief medication, antibiotics and antiseptics.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Almirall, Pfizer Inc., Greenstone LLC, F. Hoffmann-La Roche Ltd., SiriusLabs, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aegis Lifesciences Pvt. Ltd., Novartis AG, Mylan N.V., Baxter, Bayer AG, Omega Laboratories and Merck KGaA.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER